The USMLE Guys

A simple spritz into the nose...

Reversal of Alzheimer's symptoms...

A new nasal spray developed by researchers at the University of Texas Medical Branch shows promise in mouse models by targeting the pathological tau deposits responsible for Alzheimer's disease.

The novel approach circumvents the struggle faced by today's treatment modalities: Penetrating the blood-brain barrier.

A monoclonal antibody named "toxic tau conformation-specific monoclonal antibody-2" (TTCM2) is encapsulated in lipid micelles, allowing it to reach the brain with greater efficiency.

The key findings of the experiment included a reduction in tau accumulation and improved cognitive function.

This marks a significant step forward in the fight against Alzheimer's disease and other tau-related neurodegenerative disorders. It offers hope for new, non-invasive therapies that could potentially reverse or slow the progression of dementia in humans.

Stay up to date on what's new in healthcare with the weekly MedSpresso newsletter 👇

MedSpresso | Paul Ciurysek | Substack Stay Ahead of the Curve With Expert Insights on the Fast-Changing Healthcare Industry Every Sunday at 9 AM ET, Directly in Your Inbox. By Healthcare Professionals, For Healthcare Professionals. Click to read MedSpresso, by Paul Ciurysek, a Substack publication. Launched 3 days ago.

N**P Match Stats (2002-2023)... More than 12,000 spots went unfilled!! Check out the full video below:

Residency Match Stats (Unfilled Positions Since 2002) Today we're taking a look at the last 21yrs of the N**P Residency Match statistics to see which specialties have the most available and unfilled positions.Th...